Article Sidebar
Published:
Sep 6, 2024Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Modulation of inflammatory signaling pathways by natural products in osteoarthritis: Mechanisms, challenges, and future directions
Abstract
Osteoarthritis (OA) is a degenerative joint disease that is characterized by dysregulated inflammatory signaling that disrupts cartilage homeostasis and presents a significant therapeutic challenge. Although current treatments primarily focus on symptom management, this review explores the growing interest in anti-inflammatory natural products as potential disease-modifying therapies. This review aims to: identify key inflammatory pathways as promising drug targets, summarize recent findings on natural products that modulate these pathways, and discuss challenges and future directions. A comprehensive literature search was conducted using databases such as PubMed and Web of Science, focusing on studies published in the last decade. Central to OA pathogenesis is persistent inflammation resulting from cytokine /chemokine-driven catabolic signaling, which is exacerbated by the overactivation of NFκB, MAPK, and PI3K/AKT pathways. Numerous plant-derived compounds exert inhibitory effects on these inflammatory cascades through mechanisms including NF-κB nuclear translocation suppression, MAPK phosphorylation blockade, and modulation of PI3K/AKT activity. However, clinical translation faces several complexities, such as bioavailability, precise targeting, and disease heterogeneity. Addressing these challenges using advanced technologies could enable the development of natural product-based OA therapeutics. Innovative research strategies are needed to fully leverage the therapeutic potential of these compounds in the management of OA.
